Tuberculosis care among refugees arriving in Europe: a ERS/WHO Europe Region survey of current practices by Dara, M et al.
Tuberculosis care among refugees
arriving in Europe: a ERS/WHO Europe
Region survey of current practices
Masoud Dara1,15, Ivan Solovic2,15, Giovanni Sotgiu3,15, Lia D’Ambrosio4,5,15,
Rosella Centis4,15, Richard Tran1,15, Delia Goletti6, Raquel Duarte7,
Stefano Aliberti8, Fernando Maria de Benedictis9, Graham Bothamley10,
Tom Schaberg11, Ibrahim Abubakar12, Vitor Teixeira13, Brian Ward13,
Christina Gratziou14 and Giovanni Battista Migliori4
Affiliations: 1World Health Organization Office at the European Union, Brussels, Belgium. 2National Institute
for TB, Lung Diseases and Thoracic Surgery, Vysne Hagy, Catholic University Ruzomberok, Ruzomberok,
Slovakia. 3Clinical Epidemiology and Medical Statistics Unit, Dept of Biomedical Sciences, University of
Sassari - Research, Medical Education and Professional Development Unit, AOU Sassari, Sassari, Italy. 4WHO
Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri IRCCS, Tradate, Italy. 5Public Health
Consulting Group, Lugano, Switzerland. 6Translational Research Unit, Epidemiology Dept, National Institute
for Infectious Diseases, Rome, Italy. 7EPI Unit, Institute of Public Health, University of Porto, Porto, Portugal.
8School of Medicine and Surgery, University of Milan-Bicocca, UO Clinica Pneumologica, AO San Gerardo,
Monza, Italy. 9Dept of Pediatrics, Salesi Children’s Hospital Foundation, Ancona, Italy. 10Dept of Respiratory
Medicine, Homerton University Hospital NHS Foundation Trust, London, UK. 11Dept of Pneumology, Diaconess
Hospital Rotenburg/Wümme, Rotenburg/Wümme, Germany. 12Institute for Global Health, University College
London, London, UK. 13European Respiratory Society, Brussels Office, Brussels, Belgium. 14University
Respiratory Medicine Unit, Evgenidio Hospital, Athens, Greece. 15These authors contributed equally.
Correspondence: Giovanni Battista Migliori, World Health Organization Collaborating Centre for Tuberculosis
and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Via Roncaccio 16, 21049, Tradate,
Italy. E-mail: giovannibattista.migliori@fsm.it
ABSTRACT No evidence exists on tuberculosis (TB) and latent TB infection (LTBI) management
policies among refugees in European countries.
A questionnaire investigating screening and management practices among refugees was sent to 38
national TB programme representatives of low and intermediate TB incidence European countries/
territories of the WHO European Region.
Out of 36 responding countries, 31 (86.1%) reported screening for active TB, 19 for LTBI, and eight
(22.2%) reporting outcomes of LTBI treatment. Screening for TB is based on algorithms including
different combinations of symptom-based questionnaires, bacteriology and chest radiography and LTBI
screening on different combinations of tuberculin skin test and interferon-γ release assays. In 22 (61.1%)
countries, TB and LTBI screening are performed in refugee centres. In 22 (61.1%) countries, TB services
are organised in collaboration with the private sector. 27 (75%) countries answered that screening for TB
is performed as per national and international guidelines, while 19 (52.7%) gave the same answer with
regards to LTBI screening. Infection control measures are inadequate in several of the countries surveyed.
There is need for improved coordination of TB screening in Europe to implement the End TB Strategy
and achieve TB elimination.
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Introduction
According to the most recent World Health Organization (WHO) Global TB Report the estimated annual
tuberculosis (TB) incidence decreased globally by an average of 1.5% per year since 2000 and the estimated
TB prevalence in 2014 was 42% lower than in 1990 [1]. However, an estimated 9.6 million people worldwide
developed active TB in 2014, among them, 12% had HIV infection [1]. During the same year, TB caused 1.5
million deaths, making it one of the most common causes of death from an infectious disease alongside HIV.
In 2014, a total of 329270 TB cases were reported from 51 countries in the WHO European Region
(notification rate: 36.7 cases per 100000 population), with 33000 estimated deaths [2]. The estimated
incidence in Europe represents 3% of the global TB burden.
TB is considered a major public health challenge in many countries worldwide, particularly among vulnerable
populations, such as individuals at higher risk of exposure to discrimination, hostility or economic adversity.
These factors unfortunately afflict the lives of many migrants and refugees (here defined in agreement with the
1951 “Convention and Protocol relating to the status of Refugees”: www.unhcr.org/3b66c2aa10.html) [1–5].
Several factors have contributed to increase population mobility in the WHO European Region, such as
the establishment of the European Union (EU) and free movement within the Newly Independent States
(NIS), particularly for seasonal labour [5, 6], although refugees’ problems are specific. This increased
population mobility poses challenges for TB control and requires effective and sustainable mechanisms to
ensure quality TB and latent TB infection (LTBI) prevention, diagnosis and treatment [5, 7].
The need for coordinated intervention in these areas is justified from the perspective of individual human rights
(independent of legal or residential status of the subject) as well as public health pre-requisites to control and
ultimately eliminate TB, including multi- and -extensively drug resistant TB (MDR-TB and XDR-TB) [3, 8–10].
For refugees, full access to TB diagnosis and treatment (with guarantee of protection from deportation until
the end of treatment) has been recommended by WHO; this is in the interest of both the individual and the
wider hosting community in terms of TB control and elimination [11–15]. In 2015, more than one million
migrants and refugees reached Europe by land and sea. In 2014 the estimated figure was significantly lower
(219000) [4, 16]. According to official data, an estimated 181673 new refugees and migrants arrived in
Europe between January 1 and April 26, 2016, with 1261 reported deaths. 82% of arrivals via the
Mediterranean sea originated from 10 countries only [16]. At the current time, the four countries from
which most refugees originate are the Syrian Arab Republic (43% of the overall flow), Afghanistan (23%), Iraq
(14%), Pakistan (4%) and Iran (4%) (see also: http://ec.europa.eu/eurostat/statistics-explained/index.php/File:
First_time_asylum_applicants_in_the_EU-28_by_citizenship,_Q4_2014_%E2%80%93_Q4_2015.png).
Despite the recent release of resolutions and statements by bodies such as WHO, the European
Respiratory Society (ERS) and the EU [4, 17], not much is known about the policies in force in European
countries with regards to TB and LTBI management among refugees upon arrival.
In light of the ongoing refugee situation in Europe, the aim of this ERS/WHO European Region study
(performed through the ERS ad hoc Working Group on TB Advocacy) is to document the policies and
practices of low and intermediate TB incidence European countries with regards to detection and
management of TB and LTBI among refugees.
Methods
Survey questionnaire
In September–October 2015, experts from the ERS, WHO Regional Office for Europe and the WHO
Collaborating Centre in Tradate, Italy, as members of the ERS ad hoc Working Group on TB Advocacy,
(www.ersnet.org/index.php?option=com_flexicontent&view=items&id=5200-tb-advocacy-working-group.
html) developed a short questionnaire for a rapid survey containing multiple choice and open-ended
questions on screening and management of TB and LTBI among refugees in Europe. The questionnaire was
finalised after reviewing suggestions and comments received from the members of the ERS TB Advocacy
ad hoc Working Group and reaching overall consensus among the members. In addition to basic
demographic data of the respondents, the survey comprised questions on the following subject areas:
screening for and management of TB/LTBI; guidelines, legislation and evidence for current practice;
cross-border TB care; and organisational aspects of TB care and infection control measures.
The questionnaire was sent to the national TB programme representatives of all EU/European Economic
Area countries of the WHO European Region, Switzerland and six other countries who have hosted, or were
deemed likely to host, or become a transient country for a significant number of refugees in the near future.
The six additional countries were the current EU candidate countries (Albania, Bosnia and Herzegovina, the
former Yugoslav Republic of Macedonia, Montenegro, Serbia and Turkey). The survey, along with a cover
letter for additional information, was sent to each of the national TB programme representatives on October
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23, 2015, with an initial deadline set for November 6, 2015. Furthermore, there was an offer for the TB
programme representatives to conduct a telephone interview to complete the survey, should returning the
document prove too difficult by the deadline provided. On November 9, 2015, a reminder email was sent to
programme representatives who had not responded. The survey was closed on February 24, 2016.
Data analysis
The results of the survey were entered into a Microsoft Excel programme (Excel 2010; Microsoft
Corporation, Albuquerque, NM, USA) and double-checked (L. D’Ambrosio; R. Centis) prior to analysis.
Results produced a mixture of quantitative and qualitative data, with descriptive statistics being calculated
where appropriate, and supplemented with qualitative information provided by responders to the survey.
Ethics
As a broad evaluation of current policies and practices within countries, ethical approval was not required
because the study did not collect individualised information on subjects.
Results
36 (94.7%) out of 38 countries contacted responded to the questionnaire. The results from section 1
(Screening for TB and LTBI among refugees in the European Region) are summarised in table 1.
Refugees are routinely screened for active TB by the majority of the countries (31 (86.1%) out of 36), with the
exception of Italy, Monaco and Portugal where a non-systematic screening is performed (only in symptomatic
individuals); no screening is performed in Former Yugoslavia Republic of Macedonia (length of stay in
holding centre is not long enough for screening to take place) and Serbia (insufficient governmental funding).
19 (52.7%) countries (Belgium, Bulgaria, Croatia, Cyprus, Estonia, France, Greece, Iceland, Lithuania,
Luxembourg, Malta, Montenegro, Norway, Romania, Slovakia, Spain, Sweden, Turkey and the UK) screen
systematically for LTBI among refugees, eight (22.2%) countries (Denmark, Finland, Germany, Italy, Monaco,
the Netherlands, Portugal and Slovenia (which reported low numbers)) do not perform it systematically and
nine (25%) do not screen at all for LTBI (Albania, Austria, Czech Republic, Hungary, Ireland, Latvia, Former
Yugoslav Republic of Macedonia, Serbia and Switzerland) (figure 1).
However, almost half of the countries (8 (47%) out of 17) that currently do not screen for TB and LTBI
have plans to introduce it for TB and/or LTBI in the near future. There is a legal obligation to screen for
TB and/or LTBI in 21 (58.3%) of the 36 countries responding to this survey.
Screening for TB is performed with algorithms using different combinations of symptom-based
questionnaires (21 (58.3%) out of 36, of which one not systematically collected), bacteriology (18 (50%)
out of 36, sputum smear/culture collection of which nine for symptomatic individuals only) and chest
radiography (27 (75%) out of 36, of which two do not perform systematically, while in Germany, TB
screening of adult immigrants (⩾15 years old) is almost systematically performed by chest radiography
(with exception of pregnant ladies as per legal act)); five countries (Denmark, Italy, Monaco, Portugal and
Turkey) do not systematically perform any TB-specific examination. In two countries (Croatia and
Hungary), routine bacteriology for TB (sputum smear and culture) is part of the screening procedure.
Similar to the findings described by a previous ERS/WHO Europe Region Study [10], LTBI screening is
performed by using different combinations of tuberculin skin test (TST) and interferon-γ release assays
(IGRAs) in 23 (63.8%) out of 36 different European countries (eight (22.2%) out of 36, TST only, 11
(30.5%) out of 36, TST plus IGRA, four (11.1%) out of 36, TST plus IGRA in selected cases (only in
Bacillus Calmette–Guérin non-vaccinated children aged <12 years and after TB exposure in the
Netherlands; and in case of recent exposure to TB in Portugal, Slovenia and Monaco).
In 22 (61.1%) out of 36 countries, TB and LTBI screening are performed in refugee centres, using also
other combinations of measures (See table 1 for details). The decision to perform TB/LTBI screening is
determined by the TB incidence rate in the country of origin of refugees in 14 (38.8%) out of 36 of the
surveyed countries. No single threshold was provided. In the majority of countries where any screening
takes place, it is performed only once (28 (90.3%) out of 31). The results from section 2 (Management of
TB and LTBI among refugees in Europe) are summarised in table 2.
In the majority of countries (24 (66.6%) out of 36) treatment after diagnosis of active TB in a refugee is
required, whereas in Denmark, Monaco, the Netherlands and Portugal, TB treatment is voluntary; in six
other countries (Belgium, Germany, Ireland, Sweden, Switzerland and the UK) individuals cannot be legally
forced to take medications, but can usually be convinced to start anti-TB treatment; involuntary isolation is
foreseen in case of refusal to comply with treatment, while in Serbia isolation is only considered for MDR-TB
patients who refuse treatment and, in Macedonia, no TB treatment is proposed due to the short length of stay
in the country. Overall, no EU country reported that TB detection was a reason for deportation.
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Anti-TB treatment is proposed immediately after diagnosis in the majority of countries (26 (72.2%) out of
36), where costs are covered by central governmental funds (26 (72.2%) out of 36). Almost three-quarters
(23 (63.8%) out of 36) report that efforts are ongoing to adapt TB services to refugees’ specific needs
TABLE 1 Questionnaire section I: screening for tuberculosis and latent tuberculosis infection
among refugees in Europe
Active tuberculosis screening
Yes: 31/36 (86.1%)
No: 2/36 (5.2%)
Not systematically: 3/36 (8.3%)
Latent tuberculosis infection screening
Yes: 19/36 (52.7%)
No: 9/36 (25%)
Not systematically: 8/36 (22.2%)
Plans to implement screening for active tuberculosis/latent tuberculosis infection
Yes: 8/17 (47%)#
No: 5/17 (29.4%)#
Not answered: 3/17 (17.6%)#
Not applicable: 1/17 (5.9%)#
Legal requirement for screening
Yes: 21/36 (58.3%)
No: 12/36 (33.3%)
Not applicable: 3/36 (13.8%)
Active tuberculosis screening
Yes, systematic symptoms-based questionnaires: 20/36 (55.5%)
Yes, not systematic symptoms-based questionnaire: 1/36 (2.7%)
Yes, systematic bacteriology: 9/36 (25%)
Yes, bacteriology for symptomatic individuals only: 9/36 (25%)
Yes, systematic chest radiography: 25/36 (69.4%)¶
Yes, not systematic chest radiography: 2/36 (5.5%)
Other procedures: 1/36 (2.7%)+
Not systematic screening for active tuberculosis: 5/36 (13.9%)§
Routine sputum collection for microbiological study/culture/Xpert
Yes: 2/36 (5.5%)
No: 34/36 (94.4%)
Latent tuberculosis infection screening
Yes, tuberculin skin test: 19/36 (52.7%)
Yes, tuberculin skin test only: 8/36 (22.2%)
Yes, tuberculin skin test plus interferon-γ release assays: 11/36 (30.5%)
Yes, not systematic tuberculin skin test plus interferon-γ release assays: 4/36 (11.1%)
Not applicable for both: 13/36 (36.1%)
Place of screening
Refugee centres only: 10/36 (27.7%)
On arrival only: 4/36 (11.1%)
In the community only: 1/36 (2.7%)
In the National Tuberculosis Programme Centre only: 1/36 (2.7%)
On arrival and in refugee centres: 6/36 (16.6%)
On arrival and at pre-arrival: 1/36 (2.7%)
On arrival and in the community: 1/36 (2.7%)
On pre-arrival and in the community: 1/36 (2.7%)
In refugee centres and in the community: 6/36 (16.6%)
No applicable information: 5/36 (13.8%)
Information on tuberculosis rates in the country of origin to decide for the screening process
Yes: 14/36 (38.8%)
No: 19/36 (52.7%)
Not applicable: 3/36 (13.8%)
Screening number
Only once: 28/31 (90.3%)ƒ
More than once: 3/31 (9.7%)ƒ
#: denominator is the number of countries that do not (or do not systematically) screen for tuberculosis/
latent tuberculosis infection; ¶: in Germany, tuberculosis screening almost systematically performed by
chest radiography for adult immigrants (⩾15 years old); +: initial algorithm with tuberculin skin tests and
blood examination; §: numerator includes countries which do not systematically perform any examination;
ƒ: denominator is the number of countries that screen for tuberculosis/latent tuberculosis infection.
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through specific national/regional programmes and improved cooperation with the non-governmental
sector. A similar number of countries (22 (61.1%) out of 36), directly or indirectly (through certified
non-governmental organisations (NGOs)) allow refugees access to TB services. Among countries with
general or specific regional/national programmes (or guidelines) for TB management in refugees (14 (38.8%)
out of 36), more than half (nine (64.2%) out of 14) report difficulties in fully complying with requirements of
their own guidelines, given the high number of refugees in the present situation. Further details on specific
national programmes are available in table 2.
The results from section 3 (Guidelines, Legislation and Evidence on the results of screening and treatment
of TB and LTBI in Europe) are summarised in table 3. In particular, 27 (75%) 36 countries answered that
screening for TB is done as per national and international guidelines (offering the same services to
refugees and nationals), while 19 (52.7%) out of 36 gave the same answer with regards to LTBI screening.
Similarly, while 22 (61.1%) out of 36 countries confirmed that they collect data on the yield of active TB
screening among refugees (with Estonia, Finland, Norway and the UK partially/not systematically
collecting data), only 11 (30.5%) out of 36 countries (Bulgaria, Finland, France, Iceland, Italy, Lithuania,
Norway, Slovakia, Slovenia, Turkey and the UK) are equipped to collect similar data for LTBI screening
(Finland, Norway and the UK providing data not systematically). Finally, detailed information on TB
treatment outcomes is available in 19 (52.7%) out of 36 countries, while treatment completion rates for
LTBI therapy among refugees are available in only eight (22.2%) countries (Bulgaria, France, Iceland,
Netherlands, Portugal, Slovakia and Slovenia and Turkey).
The results from section 4 (Organisational aspects of TB care and infection control issues) are summarised
in table 4. Seven (19.4%) countries (Austria, Croatia, Germany, Greece, the Former Yugoslavia Republic of
Macedonia, Serbia and Turkey) reported to host >250000 refugees in the 6 months preceding the survey,
Hungary notified a range between 100001 and 250000, while Italy and Sweden reported hosting between
50001 and 100000 refugees. In the vast majority of the countries (30 (83.3%) out of 36), public sector
services are in charge of managing refugees for TB-related issues, complemented by international
organisations (e.g. Red Cross in Bulgaria, Denmark, the Former Yugoslavia Republic of Macedonia, Serbia
and Spain; the International Organization for Migration in Romania and Medicine du Monde in the UK).
Several problems were reported among the different countries, including internal and external
communication and coordination issues, cultural mediation/language differences and inadequate funding or
human resources. The sheer volume of refugees was also cited as a challenge in eight (22.2%) countries
(Austria, Belgium, Germany, Greece, Italy, the Netherlands, Norway, Serbia). Although respirators are
generally available to protect staff and complement administrative infection control measures, a general lack
of consistency with international guidelines emerged from the countries’ answers.
Active TB and LTBI screening
Active TB and not systematic LTBI screening
Active TB screening only
Not systematic active TB and LTBI screening
No active TB and LTBI screening
Not included or not reported
FIGURE 1 Summary of the countries screening for tuberculosis (TB) and latent TB infection (LTBI).
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TABLE 2 Questionnaire section II: management of tuberculosis and latent tuberculosis
infection among refugees in Europe
Procedures if active tuberculosis is diagnosed
No: refusal of asylum: 34/36 (94.4%)
Yes: obligation to undergo treatment: 24/36 (66.6%)
Other: 10/36 (27.7%)
Not applicable: 2/36 (5.5%)
Obligation to undergo treatment
Where
Treatment in hospital: 24/36 (66.6%)
Not applicable: 8/36 (22.2%)
Not answered: 4/36 (11.1%)
When
Treatment immediately started after diagnosis: 26/36 (72.2%)
Not answered 2/36 (5.5%)
Not applicable: 8/36 (22.2%)
Funding
Governmental funds: 26/36 (72.2%)
Not answered: 2/36 (5.5%)
Not applicable: 8/36 (22.2%)
Procedures if latent tuberculosis infection is diagnosed
No, refusal of asylum: 20/36 (55.5%)
Yes, obligation to undergo preventive therapy: 8/36 (22.2%)
Other: 18/36 (50%)
Not applicable: 8/36 (22.2%)
Obligation to undergo preventive therapy
Proposed to all positive for latent tuberculosis infection
Proposed to all positive for latent tuberculosis infection: 3/36 (8.3%)
No, proposed for specific groups and ages only: 7/36 (19.4%)
Not applicable: 24/36 (66.6%)
Not answered: 1/36 (2.7%)
Same procedure as native nationals positive for latent tuberculosis infection
Same procedure as native nationals positive for latent tuberculosis infection: 7/36(19.4%)
Not applicable: 24/36(66.6%)
Not answered: 5/36 (13.8%)
Therapy delivery
Therapy delivered at chest/directly observed treatment/tuberculosis centres/tuberculosis
specialists: 7/36 (19.4%)
Not applicable: 23/36(63.8%)
Not answered: 6/36 (16.6%)
Funding
Government budget: 9/36 (25%)
Not applicable: 23/36 (63.8%)
Not answered: 4/36 (11.1%)
Regional/national specific programmes for tuberculosis management in refugees
Yes: 10/36 (27.7%)
No, not fully specific: 4/36 (11.1%)
No: 22/36 (61.1%)
Regional/national programmes to provide sensitive services
Yes: 23/36 (63.8%)
No: 1/36 (2.7%)
Not answered: 12/36 (33.3%)
Special measures to deal with undocumented migrants
Yes: 22/36 (61.1%)
No: 1/36 (2.7%)
Not answered: 13/36 (36.1%)
Discrepancy/ies between guidelines and implementation
Yes: 9/36 (25%)
No: 6/36 (16.6%)
Not answered: 8/36 (22.2%)
Not applicable: 13/36 (36.1%)
Tuberculosis management funding
Government funds: 22/36 (61.1%)
Not answered: 12/36 (33.3%)
Not applicable: 2/36 (5.5%)
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Discussion
The aim of our study was to investigate which reported policies and practices exist for TB and LTBI
screening and management among refugees in low and intermediate TB incidence countries of Europe.
The survey had a very high response rate (36 (94.7%) out of 38) which shows countries’ interest and
prioritisation of this issue.
The results of our study confirm that screening for TB is considered as an important public health
measure in Europe, although significant differences exist in screening practices among countries.
According to a survey conducted in 2012 on screening practices on infectious diseases among newly
arrived migrants to Europe, all countries perform TB screening, with the second-most screened condition
being Hepatitis B (30% of the countries) [18]. The results of our survey also indicate that there is a general
lack of analysis of the yield of TB and LTBI screening among refugees. The huge workload is assumed as
the main reason. Furthermore, much less information is available for LTBI than for active TB disease.
While our survey shows that 31 countries regularly screen refugees for TB, only 19 screen for LTBI, and
even a fewer report outcomes of LTBI treatment [9]. In view of TB elimination, more and more emphasis
will be given to the possibility of implementing LTBI registers in low TB incidence countries [19].
Although 11 out of 36 countries answered they were equipped to collect information on LTBI screening,
only three (Finland, Norway and the UK) confirmed collection of data, although not systematically. LTBI
management remains a component of the TB Elimination strategy which is challenging countries,
particularly when a large number of patients is involved. In fact, the large number of arrivals in holding
centres, particularly in some European countries, makes LTBI screening and subsequent management
problematic. In addition, several countries reported difficulties in coordination between holding centres
and TB services serving the native population.
TABLE 3 Questionnaire section III: guidelines, legislation and evidence on the results of
screening and treatment of tuberculosis and latent tuberculosis in Europe
Screening and management of active tuberculosis among refugees according to national or
international guidelines/legislation in force
Yes: 27/36 (75%)
No: 3/36 (8.3%)
Not applicable: 1/36 (2.7%)
Not answered: 5/36 (13.8%)
Screening and management of latent tuberculosis infection among refugees according to national or
international guidelines/legislation in force
Yes: 19/36 (52.7%)
No: 7/36 (19.4%)
Not applicable: 5/36 (13.8%)
Not answered: 5/36 (13.8%)
Data collection in place to assess the yield of screening for active tuberculosis among refugees
Yes: 18/36 (50%)
Yes, partially or not systematically: 4/36 (11.1%)
No: 8/36 (22.2%)
Not answered: 4/36 (11.1%)
Not applicable: 2/36 (5.5%)
Data collection in place to assess the yield of screening for latent tuberculosis infection among
refugees
Yes: 8/36 (22.2%)
Yes, partially or not systematically: 3/36 (8.3%)
No: 18/36 (50%)
Not answered: 4/36 (11.1%)
Not applicable: 3/36 (8.3%)
Data collection in place to assess treatment success rates of active tuberculosis among refugees
Yes: 19/36 (52.7%)
No: 10/36 (27.7%)
Not answered: 6/36 (16.6%)
Not applicable: 1/36 (2.7%)
Data collection in place to assess completion rates of latent tuberculosis among refugees
Yes: 8/36 (22.2%)
No: 20/36 (55.5%)
Not answered: 6/36 (16.6%)
Not applicable: 2/36 (5.5%)
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Based on our survey, it appears that there are no systematic follow-up screening/check-ups of refugees for
TB sometime after their arrival. Given that refugees are often exposed to precarious, stressful travelling
conditions during transit, which provide a risk of Mycobacterium tuberculosis transmission, there is a need
to ensure people-centred care is available to them beyond arrival in their host country. Symptomatic
screening of refugees and more intensive follow-up for those with LTBI may be justified. This is
particularly important as many European countries are scaling-up their efforts to eliminate TB [10].
In an attempt to make screening as cost effective as possible, countries have applied different algorithms
in-line with WHO recommendations [20]. According to our survey, they are based on different
combinations of symptom-baseds and chest radiography, with addition of bacteriology in a few countries
(table 2). Evaluation of the yield of these screening procedures was beyond the scope of this study;
however, there is a real need for analysis of such data at national and regional level [5, 6].
Our study identified different models of screening for TB/LTBI in Europe. Some countries perform
radiological screening of all refugees in a hub or holding centre, and carry out further investigations in
decentralised centres only if radiological abnormalities are identified. Others implement different screening
algorithms or organise provision of health services differently at the refugee centres. In this context,
screening for LTBI, by use of IGRAs and/or TST, although considered an important intervention in the
pursuit of TB Elimination [9, 10] is still difficult to implement in several countries.
Based on the unprecedented number of refugees, it is important to have a specific response plan and
ensure its full funding both at the national and European level. Interestingly, in the majority of countries
(22 (61.1%) out of 36), TB services are organised in collaboration with NGOs and other sectors. Among
others benefits, this approach has the advantage of increasing cultural sensitivity of the TB services.
TABLE 4 Questionnaire section IV: organisational aspects of tuberculosis care and infection
control issues
Number of refugees hosted at the national level during the past 6 months
<50000: 25/36 (69.4%)
50001–100000: 2/36 (5.5%)
100001–250000: 1/36 (2.7%)
>250000: 7/36 (19.4%)
Not answered: 1/36 (2.7%)
Organisation(s) responsible for first-line medical care of refugees at the national level
National and/or local medical/public health services (including Ministry of Health): 21/36 (58.3%)
Medical staff of holding centres: 3/36 (8.3%)
Primary healthcare clinics: 3/36 (8.3%)
Federal/State Agencies for Refugees: 3/36 (8.3%)
Red Cross/international organisations:6/36 (16.6%)
Public/private providers: 1/36 (2.7%)
Special measures for cross-border care when a refugee is diagnosed active tuberculosis
Yes: 17/36 (47.2%)
No: 14/36 (38.8%)
Not answered: 3/36 (8.3%)
Not applicable: 2/36 (5.5%)
Priority problems identified at the national level to manage tuberculosis among refugees
System in place overloaded by the recent increase of migrants/suboptimal coverage of screening and
contact-tracing (high screening numbers, separate registers), organisations/public health services
understaffed regarding the workload (delay and difficulties in diagnosis, treatment, care and follow-
up/treatment and care/organise cross-border care/low compliance, many lost-to-follow-up under
tuberculosis treatment and continuing migration mobility: 22/36 (61.1%)
Major barriers to access healthcare services related to cultural, religious, and language
differences/lack of knowledge about tuberculosis, lack of information about the healthcare
system in the country and cultural constraints/stigmatisation of tuberculosis patients/insufficient
patient counselling and motivation: 13/36 (36.1%)
Lack of coordination among involved entities: 6/36 (16.6%)
Logistical problems: 10/36 (27.7%)
Personal protection/infection control measures in place for presumptive active tuberculosis cases
Respirators used for staff and surgical masks for individuals with possible tuberculosis or other
respiratory disease: 24/36 (66.6%)
Only respirator used for staff in contact with refugees: 1/36 (2.7%)
Other: 7/36 (19.4%)
Not answered: 4/36 (11.1%)
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Infection-control measures are generally inadequate in a large proportion of the countries surveyed.
Surgical masks are often used to “protect” healthcare workers when it is well known that they are ineffective
against M. tuberculosis from active TB patients who are not on treatment; certified respirators are needed
for this purpose. Furthermore, a lack of specific training on infection control measures has been reported.
Similar problems have previously been described in European MDR-TB reference centres [21].
Although surveys of this kind are subject to several limitations (related to the instrument used, the missing
information from non-responding countries, the possible erroneous responses from national programmes
and the limitations of aggregated data), strengths of this study include: continuous dialogue with National
TB representatives; the very high response rate (94.7%); and the consistency of the answers received with
previous surveys carried out using similar methodology [10].
The results of the present study highlight the need for improved coordination of TB screening in Europe,
with the ultimate goal of implementing the End TB Strategy, the TB Action Plan for the WHO European
Region 2016–2020 [22] and the Health 2020 Policy Framework [23] to address inequity. The ultimate goal
of these strategies is to achieve TB Elimination [9, 10, 24, 25]. This will require quality operational research
evaluating surveillance (aimed at attaining better data for better planning), the efficacy of existing
algorithms and the yield of screening activities [26]. Furthermore, within the limited information available
on LTBI in the European context, further clinical and operational research is also needed to inform
clinicians and public health authorities on the correct approach to follow when LTBI is diagnosed in
contacts of MDR-TB cases.
Finally, the new function of the ERS/WHO Europe TB Consilium (a free, internet-based instrument
supporting clinicians to manage difficult-to-treat cases of tuberculosis) is now live and accessible under the
TB Consilium website (www.tbconsilium.org). This electronic platform will allow better cross-border TB
control by contributing to the provision of quality prevention, diagnostic and treatment services to migrants
and refugees.
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